Aurora Stock: Will it Gain Big or Go Bust in 2020?

After falling 93% from record highs, Aurora Cannabis (TSX:ACB)(NYSE:ACB) now trades at $1. Should investors give up on Aurora stock?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks have burnt significant investor wealth in the last year. Giants such as Aurora Cannabis (TSX:ACB)(NYSE:ACB) have lost massive market value. Aurora stock is currently trading at $1.02, which is 93% below record highs. The euphoria surrounding cannabis legalization that drove investor optimism and stocks higher in late 2018 seems a distant dream.

The ongoing COVID-19 pandemic has further pressurized this sector. Several companies, including Aurora Cannabis, are still grappling with mounting losses. Lower consumer demand will wreak havoc on company financials in the coming months.

Aurora Cannabis remains one of the most-held stocks on Robinhood — an investment platform targeted at millennials. Aurora stock crushed equity markets, as its price rallied from $0.40 in May 2015 to $13.7 in October 2018. It gained a staggering 3,200% in just over three years. But a majority of these gains have been wiped out since. In the last five years, Aurora stock is up 155%.

Let’s take a look at see if Aurora stock is a good buy at the current price. Will it roar back to life in 2020 or continue to disappoint investors?

Aurora Cannabis is burning through cash

One of the major concerns for investors is the precarious cash position of Aurora Cannabis. The company has continued to raise capital to keep running operations over the years. Since 2014, its share count has risen from 16 million to 1.17 billion, according to data from Yahoo! Finance. The company’s board of directors approved another US$350 million in a share offering last month.

Over the years, Aurora Cannabis has acquired several companies at sky-high valuations. Back then, the company would have bet on the rapidly expanding cannabis market in Canada to create demand. However, pot companies have been impacted by structural issues and lower-than-expected demand.

Aurora Cannabis’s goodwill impairment figure in the fiscal second quarter of 2020 stood at $762 million. Its goodwill currently stands at $2.41 billion and accounts for 52% of total assets. It has a market cap of $1.33 billion. While goodwill writedowns will concern investors, Aurora’s rising inventory levels will impact financials this year.

Aurora Cannabis is also facing liquidity issues. At the end of 2019, its estimated short-term liabilities stood at $374 million. It ended last year with a cash balance of just over $200 million.

Is the end near for Aurora stock?

Aurora Cannabis is still one of the major marijuana producers in the world. It can grow close to 700,000 kg at peak production capacity and has wholesale supply agreements in 24 international markets.

To continue listing on the New York Stock Exchange, the company will shortly enact a 1-for-12 reverse stock split this month. While a higher Aurora stock price will keep it on the NYSE, the company is losing ground in terms of its weak fundamentals.

There are just too many questions for investors right now. The company’s lack of capital and liquidity coupled with the ongoing uncertainty surrounding COVID-19 and the slow rollout of retail stores in Canada’s major provinces mean Aurora Cannabis stock might move lower in the next few months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »